Send me real-time posts from this site at my email

Strength Seen in PTC Therapeutics (PTCT): Can Its 5.1% Jump Turn into More Strength?

PTC Therapeutics (PTCT) shares ended the last trading session 5.1% higher at $40.03. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 7.7% gain over the past four weeks.

The stock rallied after the company provided robust preliminary financial results for 2021 and financial guidance for 2022.

This biopharmaceutical company is expected to post quarterly loss of $1.98 per share in its upcoming report, which represents a year-over-year change of -83.3%. Revenues are expected to be $134.21 million, up 12.9% from the year-ago quarter.

Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.

For PTC Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on PTCT going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank 3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>


Zacks’ Top Picks to Cash in on Artificial Intelligence

This world-changing technology is projected to generate $100S of billions by 2025. From self-driving cars to consumer data analysis, people are relying on machines more than we ever have before. Now is the time to capitalize on the 4th Industrial Revolution. Zacks’ urgent special report reveals 6 AI picks investors need to know about today.

See 6 Artificial Intelligence Stocks With Extreme Upside Potential>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
PTC Therapeutics, Inc. (PTCT): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue